clinical trial · NCT04924192
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase2·terminated·n = 21
Advanced Lung CarcinomaTQB3616 capsulesAnlotinib Hydrochloride capsulesIrinotecan Hydrochloride for Injection
brief summary
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
started
Aug 18, 2021
primary completion
Sep 27, 2022
completion
Oct 10, 2022
last updated
Apr 13, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol